|Bid||45.53 x 1000|
|Ask||45.54 x 900|
|Day's range||44.54 - 45.83|
|52-week range||43.25 - 89.70|
|Beta (5Y monthly)||0.59|
|PE ratio (TTM)||22.71|
|Earnings date||09 Feb 2023|
|Forward dividend & yield||1.16 (2.54%)|
|Ex-dividend date||01 Dec 2022|
|1y target est||58.01|
Quipt Home Medical Corp. (QIPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EDEN PRAIRIE, Minn. & DEERFIELD, Ill., February 01, 2023--Miromatrix Medical Inc. (NASDAQ: MIRO) and Baxter International Inc. (NYSE:BAX) today announced a collaborative research agreement to help support additional treatment options for patients with acute liver failure (ALF) in need of organ support therapies. As part of the collaboration, Miromatrix has created a new liver therapy called miroliverELAP that combines a Miromatrix single-use bioengineered liver with Baxter’s PrisMax system. Miro